DP
CAPR icon

Diadema Partners’s Capricor Therapeutics CAPR Stock Holding History

Diadema Partners’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.4M Sell
78,851
-79,224
-50% -$2.11M 0.41% 54
2025
Q4 		$4.56M Buy
+158,075
New +$2.06M 0.79% 35

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Diadema Partners's CAPR Position: Q1 2026 in Review

Diadema Partners reduced its Capricor Therapeutics (CAPR) stake by 50% in Q1 2026, selling an estimated $2.11M and leaving 78,851 shares worth $2.4M. The position accounts for 0.41% of the portfolio, ranked #54.

Diadema Partners first reported a position in CAPR in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.56M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Diadema Partners held 78,851 shares of Capricor Therapeutics worth $2.4M as of Q1 2026.
  • Diadema Partners sold 79,224 Capricor Therapeutics shares in Q1 2026, an estimated $2.11M.
  • Capricor Therapeutics made up 0.41% of Diadema Partners's portfolio in Q1 2026, its #54 holding.
  • Diadema Partners first reported a position in Capricor Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Diadema Partners's Capricor Therapeutics position peaked at $4.56M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.